Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

被引：1
|
作者：
Haddad, Tufia C.
Suman, Vera
Giridhar, Karthik V.
Moreno-Aspitia, Alvaro
Northfelt, Donald
Ernst, Brenda
Sideras, Kostandinos
O'Sullivan, Ciara C.
Singh, Ravinder
Desta, Zeruesenay
Taraba, Jodi
Goodnature, Barbara
Goetz, Matthew P.
Wang, Liewei
Ingle, James N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT1-04-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-04-02
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Exemestane versus anastrozole in postmenopausal women with hormone positive early breast cancer (EBC)
    Abdel-Halim, I.
    El-Sadda, W.
    El-Sherbeiny, E.
    El-Ebrashy, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S49 - S49
  • [22] Letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare benefit
    Rourke, M.
    Dranitsaris, G.
    Kaura, S.
    Rugo, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women
    Milani, Monica
    Jha, Gautam
    Potter, David A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 141 - 156
  • [24] Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer
    Carlson, R. W.
    O'Neill, A.
    Vidaurre, T.
    Gomez, H. L.
    Badve, S.
    Sledge, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer A Randomized Clinical Trial
    Serrano, Davide
    Gandini, Sara
    Thomas, Parjhitham
    Crew, Katherine D.
    Kumar, Nagi B.
    Vornik, Lana A.
    Lee, J. Jack
    Veronesi, Paolo
    Viale, Giuseppe
    Guerrieri-Gonzaga, Aliana
    Lazzeroni, Matteo
    Johansson, Harriet
    D'Amico, Mauro
    Guasone, Flavio
    Spinaci, Stefano
    Bertelsen, Bjorn-Erik
    Mellgren, Gunnar
    Bedrosian, Isabelle
    Weber, Diane
    Castile, Tawana
    Dimond, Eileen
    Heckman-Stoddard, Brandy M.
    Szabo, Eva
    Brown, Powel H.
    DeCensi, Andrea
    Bonanni, Bernardo
    JAMA ONCOLOGY, 2023, 9 (05) : 664 - 672
  • [26] Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III)
    Rosati, M. S.
    Di Seri, M.
    Baciarello, G.
    Russo, V. L. O.
    Grassi, P.
    Marchetti, L.
    Giovannoni, S.
    Basile, M. L.
    Frati, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole
    Kalder, Matthias
    Ziller, Volker
    Kyvernitakis, Ioannis
    Knoell, Dana
    Hars, Olaf
    Hadji, Peyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 915 - 923
  • [28] Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: a meta-analysis
    Jonat, Walter
    Gnant, Michael
    Boccardo, Francesco
    Kaufmann, Manfred
    Rubagotti, Alessandro
    Zuna, Ivan
    Greenwood, Mike
    Jakesz, Raimund
    LANCET ONCOLOGY, 2006, 7 (12): : 991 - 996
  • [29] Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer
    Sawada, S
    Sato, K
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S31 - S32
  • [30] COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
    Rudakova, A., V
    VALUE IN HEALTH, 2009, 12 (07) : A276 - A276
12345